This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sawada, K. Articles by Lengyel, E. Search for Related Content PubMed PubMed Citation Articles by Sawada, K. Articles by Lengyel, E.

Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via ₅-Integrin, which Is a Therapeutic Target

¹ Departments of Obstetrics and Gynecology/Section of Gynecologic Oncology, ² Health Studies, ³ Pathology, ⁴ Ben May Department for Cancer Research, and ⁵ Committee on Cancer Biology, University of Chicago, Chicago, Illinois and ⁶ PDL BioPharma, Fremont, California

Requests for reprints: Ernst Lengyel, University of Chicago, Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, MC 2050, 5841 South Maryland Avenue, Chicago, IL 60637. Phone: 773-7026722; Fax: 773-7025411; E-mail: elengyel{at}uchicago.edu.

Key Words: ovarian cancer • prognosis • metastasis • 5β1-integrin • E-cadherin • EGFR

E-cadherin loss is frequently associated with ovarian cancer metastasis. Given that adhesion to the abdominal peritoneum is the first step in ovarian cancer dissemination, we reasoned that down-regulation of E-cadherin would affect expression of cell matrix adhesion receptors. We show here that inhibition of E-cadherin in ovarian cancer cells causes up-regulation of ₅-integrin protein expression and transcription. When E-cadherin was blocked, RMUG-S ovarian cancer cells were able to attach and invade more efficiently. This greater efficiency could, in turn, be inhibited both in vitro and in vivo with an ₅β₁-integrin–blocking antibody. When E-cadherin is silenced, ₅-integrin is up-regulated through activation of an epidermal growth factor receptor/FAK/Erk1–mitogen-activated protein kinase–dependent signaling pathway and not through the canonical E-cadherin/β-catenin signaling pathway. In SKOV-3ip1 ovarian cancer xenografts, which express high levels of ₅-integrin, i.p. treatment with an ₅β₁-integrin antibody significantly reduced tumor burden, ascites, and number of metastasis and increased survival by an average of 12 days when compared with IgG treatment (P < 0.0005). ₅-Integrin expression was detected by immunohistochemistry in 107 advanced stage ovarian cancers using a tissue microarray annotated with disease-specific patient follow-up. Ten of 107 tissues (9%) had ₅-integrin overexpression, and 39% had some level of ₅-integrin expression. The median survival for patients with high ₅-integrin levels was 26 months versus 35 months for those with low integrin expression (P < 0.05). Taken together, we have identified ₅-integrin up-regulation as a molecular mechanism by which E-cadherin loss promotes tumor progression, providing an explanation for how E-cadherin loss increases metastasis. Targeting this integrin could be a promising therapy for a subset of ovarian cancer patients. [Cancer Res 2008;68(7):2329–39]